Merrill: Confidence...
Health Care: Drugs
Vical Incorporated (VICL: NASDAQ)
$3.63 0.02 | 0.55%
05/21/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -22.90M | -7.28M | -30.38M | -28.56M |
| Operating Gains/Losses | -9.00K | 0.00 | 0.00 | -5.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 977.00K | -2.19M | 409.00K | 503.00K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -792.00K | -51.00K | -1.77M | 1.85M |
| (Decrease) Increase In Other Current Liabilities | -247.00K | -169.00K | -83.00K | 0.00 |
| (Increase) Decrease In Other Working Capital | 51.00K | 366.00K | -1.99M | 255.00K |
| Other Non-Cash Items | 3.36M | 3.18M | 2.78M | 1.88M |
| Net Cash From Continuing Operations | -17.57M | -3.85M | -28.23M | -21.45M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -17.57M | -3.85M | -28.23M | -21.45M |
| Sale of Property, Plant & Equipment | 9.00K | 0.00 | 0.00 | 10.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 16.02M |
| Purchases of Property, Plant & Equipment | -1.06M | -662.00K | -760.00K | -652.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | -24.66M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -26.64M | -4.83M | 12.51M | -9.28M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 48.93M | 214.00K | 37.26M | 33.04M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | -156.00K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -253.00K | -159.00K | -92.00K | -37.00K |
| Net Cash From Financing Activities | 48.68M | 55.00K | 37.17M | 32.84M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 4.46M | -8.62M | 21.45M | 2.11M |
Portfolios with VICL
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor22 Biopharma Stocks With Br...
- UserO4 Investing
- ContributorStocks With Big Insider Buy...
- Contributor10 Best-Performing Stocks U...
- ContributorRelative Strength Stocks 09...
- ContributorCancer Drug Stocks to Trade...
- ContributorBreakout Stocks Of The Week...
- ContributorDollar Store
Latest VICL Headlines from TheStreet
- Interesting VICL Put And Call For July 05.20.13 | 03:05 pm
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma 05.17.13 | 07:05 am
- Short Interest In Vical Moves 21.2% Higher 05.10.13 | 03:05 pm
- Vical Reports First Quarter 2013 Financial Results And Progress In Key Development Programs 05.09.13 | 06:05 am
- Vical To Present At May Investor Conferences 05.07.13 | 06:05 am
- Vaxfectin(R) Enhances Preclinical Immune Responses To Baxter's Cell Culture-Derived Influenza Vaccines 05.06.13 | 06:05 am
- Vical Announces News Release And Conference Call Schedule For First Quarter 2013 Financial Results 05.02.13 | 06:05 am
- Vical CEO To Participate In Cancer Immunotherapy Panel At BIO International Convention 04.22.13 | 06:04 am
- 6 Stocks Under $10 Spiking Higher 04.04.13 | 03:04 pm
- 16 Stocks Under $5 Trading At Discounts To Target Price 03.26.13 | 12:03 pm
Press Releases for VICL
- MERIAL Receives Full License Approval For ONCEPT(TM) Canine Melanoma Vaccine - PR Newswire 02.16.10 | 08:02 am
Partner Headlines for VICL
- Vical and Bristol-Myers Ink Deal - Analyst Blog - NASDAQ 09.17.12 | 07:09 pm
- Abbott-Astellas Collaborate - Analyst Blog - NASDAQ 09.13.12 | 10:09 pm
- Abbott-Astellas Collaborate - Analyst Blog - Zacks 09.13.12 | 06:09 pm
- 3 Vaccine Companies With Upcoming Catalysts - Seeking Alpha 09.09.12 | 08:09 am
- 3 Speculative Biotechs Worth Watching - Seeking Alpha 07.08.12 | 08:07 am
- Vical Back On The Move - Seeking Alpha 11.04.11 | 06:11 pm
- Vical: Making Progress In The Area Of HSV-2 Vaccines - Seeking Alpha 08.26.11 | 10:08 pm
- 5 Healthcare Stocks of Interest This Week - Seeking Alpha 07.15.11 | 06:07 pm
- Vical Is Deeply Undervalued: Technology and Pipeline Offer Upside Reward - Seeking Alpha 03.29.11 | 08:03 am
- Ipilimumab Approval Highlights Active Immunotherapy Renaissance - Seeking Alpha 03.27.11 | 08:03 am
